Abstract:Background: Evidence from clinical trials of early pulsed field ablation (PFA) systems in treating atrial fibrillation has demonstrated their promising potential to reduce complications associated with conventional thermal modalities while maintaining efficacy. However, the lack of a fully integrated mapping system, a staple technology of most modern electrophysiology procedures, poses limitations in lesion creation and workflow options. A novel variable-loop PFA catheter integrated with an electroanatomic mapping system has been developed that allows for real-time nonfluoroscopic procedural guidance and lesion indexing as well as feedback of tissue-to-catheter proximity. AdmIRE (Assessment of Safety and Effectiveness in Treatment Management of Atrial Fibrillation With the Bosense-Webster Irreversible Electroporation Ablation System), a multicenter, single-arm, Food and Drug Administration investigational device exemption study, evaluated the long-term safety and effectiveness of this integrated PFA system in a large United States-based drug-refractory symptomatic paroxysmal atrial fibrillation patient population. Methods: Using the PFA catheter with a compatible electroanatomic mapping system, patients with drug-refractory symptomatic paroxysmal atrial fibrillation underwent pulmonary vein isolation. The primary safety end point was primary adverse event within 7 days of ablation. The primary effectiveness end point was a composite end point that included 12-month freedom from documented atrial tachyarrhythmia (ie, atrial fibrillation, atrial tachycardia, atrial flutter) episodes, failure to achieve pulmonary vein isolation, use of a nonstudy catheter for pulmonary vein isolation, repeat procedure (except for one redo during blanking), taking a new or previously failed class I or III antiarrhythmic drug at higher dose after blanking, or direct current cardioversion after blanking. Results: At 30 centers, 277 patients with paroxysmal atrial fibrillation (61.5±10.3 years of age; 64.3% male) in the pivotal cohort underwent PFA. More than 25% of the procedures were performed without fluoroscopy. Median (Q1, Q3) pulmonary vein isolation procedure, fluoroscopy, and transpired PFA application times were 81.0 (61.0, 112.0), 7.1 (0.00, 14.3), and 31.0 (24.8, 40.9) minutes, respectively. The primary adverse event rate was 2.9% (8 of 272), with the most common complication being pericardial tamponade. The 12-month primary effectiveness end point was 74.6%. The 1-year freedom from atrial fibrillation, atrial tachycardia, or atrial flutter recurrence rate after blanking was 75.4%. Substantial improvements in quality of life were observed as early as 3 months after the procedure, concurrent with a reduction in multiple health care use measures. Conclusions: AdmIRE confirmed the safety and effectiveness of the variable-loop PFA catheter, with short procedure and PFA application times and low fluoroscopy exposure. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT05293639.

Safety and Efficacy of PathBuilderTM Transseptal Puncture System for Atrial Fibrillation Therapy:A Multi-Center Prospective Controlled Clinical Trial

Potential Maintenance Mechanism in Atrial Fibrillation Patients Subject to Different Treatment Procedures: A Preliminary Study Based on a Human Atrial Model

Prospective Randomized Comparison Between Upgraded?2c3l? Vs. PVI Approach for Catheter Ablation of Persistent Atrial Fibrillation: PROMPT-AF Trial Design

Treatment of Long-Standing Persistent Atrial Fibrillation by Linear Ablation

Clinical Comparison of Circumferential Pulmonary Vein Ablation of Atrial Fibrillation with and Without the Assistance of MERGE Technique under the Guidence of CARTO System

Pulmonary Vein Isolation with Optimized Linear Ablation Vs Pulmonary Vein Isolation Alone for Persistent AF: the PROMPT-AF Randomized Clinical Trial.

Prospective randomized comparison between upgraded ‘2C3L’ vs. PVI approach for catheter ablation of persistent atrial fibrillation: PROMPT-AF trial design

Clinical Evaluation of Circumferential Ultrasound Ablation of Pulmonary Veins for Patients with Paroxysmal Atrial Fibrillation

Ultrasound Ablation of Pulmonary Veins for Treatment of Paroxysmal Atrial Fibrillation

A pilot clinical assessment of biphasic asymmetric pulsed field ablation catheter for pulmonary vein isolation

Real-world effectiveness and safety of a contact force-sensing catheter for atrial fibrillation ablation in China

Segmental radiofrequency ablation of pulmonary vein ostia for patients with refractory paroxysmal atrial fibrillation using multi-slice spiral computed tomography guidance

Efficacy and safety of a novel hexaspline pulsed field ablation system in patients with paroxysmal atrial fibrillation: the PLEASE-AF study

Pulsed Field Ablation for the Treatment of Atrial Fibrillation: PULSED AF Pivotal Trial

Pulsed Field Ablation to Treat Paroxysmal Atrial Fibrillation: Safety and Effectiveness in the AdmIRE Pivotal Trial

Efficacy and safety of circumferential pulmonary vein ablation combined complex fractionated atrial electrograms ablation for atrial fibrillation

Application of combined ablation procedures via percutaneous epi/endocardial access in patients with recurrent atrial fibrillation

Dual-energy lattice-tip ablation system for persistent atrial fibrillation: a randomized trial

Preclinical Study of Biphasic Asymmetric Pulsed Field Ablation

Multi-centre, Prospective Randomized Comparison of Three Different Substrate Ablation Strategies for Persistent Atrial Fibrillation

Safety and Effectiveness of Pulsed Field Ablation to Treat Atrial Fibrillation: One-Year Outcomes From the MANIFEST-PF Registry